Matthew Rabinowitz

Executive Chairman Rabinowitz sold 100,000 shares for $21.4M via pre-arranged 10b5-1 plan (2026-06-12 to 06-15)

Matthew Rabinowitz executed 21 separate sales totaling 100,000 shares (100.0K shares) for $21,447,307.52 across two trading days under a 10b5-1 trading plan adopted on 2026-03-13, meaning this was a scheduled transaction rather than a discretionary decision. The blended average price was $214.47, within the company's recent 52-week range of $131.81–$256.36. His post-transaction holdings of 2,277,843 shares (2.28M shares) represent a net reduction of 4.2% from pre-transaction levels. The company currently trades at $220.11 and reports $696.6M in quarterly revenue with annual growth of 35.9%, though it posted a net loss of $85.1M in the most recent quarter, indicating growth without current profitability; the scheduled nature of this sale under a pre-arranged plan limits inference about timing signals.

Executive Chairman Rabinowitz sells ~7,708 shares across five transactions; stock near 52-week lows following sustained gains.

Matthew Rabinowitz, Executive Chairman of Natera, executed a series of sales totaling approximately 7,708 shares between May 4 and May 5, representing meaningful portfolio activity for an officer with direct operational knowledge. The timing coincides with the stock trading significantly below its 52-week high, suggesting he is not selling into momentum. Rabinowitz's track record consists entirely of prior sales—twenty consecutive sell transactions with no record of purchases—yet those prior sales have demonstrated poor exit timing, with the stock subsequently appreciating after each prior sale. Against this backdrop of unsuccessful timing on prior exits, he is again selling, now when the company remains unprofitable despite substantial revenue growth. The combination of repeated selling by someone with operational knowledge, coupled with his demonstrated inability to time exits well in this stock previously, creates a conflicting signal: his consistent selling behavior suggests caution about the company's direction, but his poor historical timing implies skepticism about his ability to identify the right selling opportunities.

Executive Chairman Rabinowitz sold 200,000 shares (200.0K shares) for $38,283,381.64 ($38.3M) over three days at blended avg $191.42

Matthew Rabinowitz, Executive Chairman of Natera (NTRA), executed 23 separate sales totaling 200,000 shares (200.0K shares) for $38,283,381.64 ($38.3M) on March 12–16, 2026, reducing his holdings by 8.0% to 2,310,772 shares (2.31M shares). The multi-day, multi-tranche execution structure across a narrow price range ($186.75–$198.02) is distinct from a single large block sale. Over his prior five sales at NTRA, Rabinowitz achieved zero well-timed outcomes at the 90-day mark—all generated positive returns, meaning the stock rose after each sale and he missed subsequent gains. The company generated positive annual revenue growth of 35.9% but posted a full-year net loss, with the most recent quarter showing a $-87,544,000.00 net loss on $592,183,000.00 revenue. Current price of $197.68 is 22.3% below the 52-week high and down 4.2% over 30 days, creating a markedly different valuation backdrop than prior sales in September–November 2025.

Rabinowitz sells 22,900 NTRA shares for $4,591,674.03 across 2 transactions at $200.51 avg; retains 2,280,852 shares post-sale.

Matthew Rabinowitz, Executive Chairman of Natera, executed 2 separate sales totaling 22,900 shares for $4,591,674.03 on 2025-11-04 at a blended average price of $200.51. This represents a 1.0% reduction from his pre-transaction holdings of 2,303,752 shares, leaving him with 2,280,852 shares. The sale occurred near NTRA's 52-week high of $198.93, and Rabinowitz's prior transaction history at NTRA shows 5 recent sales (dating back to 2025-09-18) with mixed near-term results: the 3 measurable 30-day outcomes ranged from +0.2% to +0.9%, while 90-day outcomes remain pending. His broader cross-ticker track record of 20 prior sells shows an average 90-day return of +2.7%, indicating that his prior sell-timing has historically been unprofitable (positive returns after sells mean he exited ahead of gains). Against this backdrop, the stock has rallied +42.2% over 90 days and +17.4% over 30 days, yet Natera remains unprofitable with a full-year net income of $-100,938,000.00 despite strong revenue growth of +56.8% year-over-year.

Executive Chairman Rabinowitz sold 17,100 shares of NTRA at $200.00 on 2025-11-03 for $3,420,003.42; stock up 41.5% in 90 days, near 52-week high of $198.93.

Matthew Rabinowitz, Executive Chairman, sold 17,100 shares at $200.00, reducing holdings from 2,320,852 to 2,303,752 shares (-0.7%). The transaction occurred as NTRA trades near its 52-week high of $198.93, following strong momentum: +41.5% over 90 days and +18.4% over 30 days. Rabinowitz's cross-ticker track record shows 20 prior open-market sales with a well-timed rate of 26.67%, but his same-ticker history at NTRA reveals 5 prior sells with 0 of 0 measurable 90-day outcomes showing well-timed results. The company remains unprofitable (net income $-100,938,000.00) despite robust revenue growth of +56.8% year-over-year, creating a valuation backdrop where insider dispositions merit scrutiny alongside fundamental execution risks.

NTRA Executive Chairman Rabinowitz sells 10,000 shares (66.7% of holdings) for $1.9M at $190.00

Matthew Rabinowitz, Executive Chairman of Natera, sold 10,000 shares at $190.00 on 2025-10-20, reducing his holdings from 15,000 to 5,000 shares—a 66.7% reduction. The sale occurred at a price $2.58 above the current market price of $188.02 and very close to the 52-week high of $188.60 (0.3% below). At the same-ticker level, Rabinowitz's prior five trades at NTRA show mixed outcomes: four recent sales in September 2025 posted modest 30-day returns of +0.6%, +0.2%, +0.9%, and +0.9%, while a June 2025 sale fell 3.3% in 30 days but recovered to +4.8% by day 90. His cross-ticker track record shows a 90-day well-timed rate of 31.25% across 20 prior sales. Natera remains unprofitable despite strong revenue growth of +56.8%, with the latest quarter showing $546.6M in revenue against a net loss of $100.9M. The substantial concentrated reduction in holdings by the Executive Chairman warrants monitoring alongside the company's unprofitable growth trajectory.

Executive Chairman Rabinowitz sells 50,000 NTRA shares for $9.0M as stock hits 52-week high of $181.11

Matthew Rabinowitz, Executive Chairman of Natera, executed 4 separate sales totaling 50,000 shares for $9,016,668.35 at prices ranging from $180.00 to $181.28 on September 18–19, 2025, reducing his holdings by 2.1% to 2,320,852 shares. The sales occurred as NTRA stock reached its 52-week high of $181.11 and gained +12.7% over the prior 30 days and +5.4% over 90 days. Rabinowitz's prior sales at NTRA (5 trades in the last 4 months, from May 16 through June 13) generated positive 90-day returns in all cases (ranging from +2.9% to +4.8%), indicating none were well-timed by the standard of preceding a subsequent decline. The company remains unprofitable with a net income of $-100,938,000.00 on revenue of $546,600,000.00 (latest quarter), though annual revenue growth reached +56.8%. The sale at near-record prices follows a consistent pattern of open-market dispositions by the same insider but provides no clear signal of forward conviction given the prior execution outcomes and the company's current profitability profile.

Executive Chairman Rabinowitz sells 54,000 shares ($8.4M) over 4 weeks; 64.3% reduction in holdings; stock up 13.8% (30-day)

Matthew Rabinowitz, Executive Chairman of Natera Inc., executed 6 separate sales totaling 54,000 shares for $8,384,150.00 between May 15 and June 13, 2025, at prices ranging from $150.20 to $165.85 (blended average $155.26). The sales reduced his holdings from 84,000 shares to 30,000 shares, a -64.3% reduction. The stock has since appreciated 13.8% (30-day) and 13.7% (90-day) from the transaction window, now trading at $171.86. His 5 prior sales at this ticker (all on 2025-03-14) had 0 out of 5 well-timed results at the 90-day horizon, and his cross-ticker track record shows 16 prior sells with a 31.25% well-timed rate, both below-average for sell-timing accuracy. Against the backdrop of the company reporting positive 56.8% annual revenue growth but $-66.9M net income (unprofitable), the size and pace of this disposal—divesting two-thirds of his position—merits investor attention for what it signals about Executive Chairman conviction.

Executive Chairman sells 50,000 NTRA shares for $7.4M across 5 transactions; stock down 13.8% in 30 days.

Matthew Rabinowitz executed 5 separate sales totaling 50,000 shares for $7,385,248.66 at blended average $147.70 on March 14, 2025. The stock has declined 13.8% over the prior 30 days and is down 16.3% from its 52-week high of $177.00, trading near the upper end of its range at $148.22 current price. Rabinowitz retains 2,365,415 shares post-transaction, representing a 2.1% reduction of his holdings. His prior trades at NTRA show a consistent pattern: all 5 previous sales were well-timed, with negative 90-day returns ranging from -13.4% to -15.4%, indicating sales executed before subsequent declines. The company carries a P/E of 673.73 on negative net income of $-31,592,000.00 over its latest fiscal year, despite strong 56.8% annual revenue growth. This sale occurs within the context of recent stock weakness and a track record of disciplined sale execution at this ticker.

Executive Chairman Matthew Rabinowitz sold 160,000 shares (160.0K shares) for $26,518,749.53 across 5 transactions on 2024-12-13

Matthew Rabinowitz, Executive Chairman of Natera, executed 5 separate sales totaling 160,000 shares for $26,518,749.53 on 2024-12-13, reducing his holdings by 6.3% to 2,389,180 shares. The blended average sale price of $165.74 sits 0.5% above the current price of $166.55 and 4.3% below the 52-week high of $174.00, placing the sales in the upper range of recent trading. Natera trades at $22.0B market cap while reporting negative full-year net income of $-31,592,000.00 against $439.8M quarterly revenue and 32.0% annual growth. His prior 5 sales at NTRA showed uniformly positive 90-day returns (ranging 22.2%–24.7%), meaning each prior sale was followed by stock appreciation rather than decline; this pattern suggests timing has not been predictive of near-term downside at this ticker. The large magnitude and multi-tranche execution on a single date distinguishes this from his typical smaller sales and warrants monitoring of subsequent 90-day price action.